Preview Newsletter

XARELTO Media Monitoring – Week of 01-15-16

Client Attorney Privileged/Attorney Work Product/At Request of Counsel

Plaintiff Attorney Press Releases

90-Count Xarelto Lawsuit Requests $4.35 Million In Compensation For Alleged Bleeding Events
Jan 8, 2016 | Blood Thinner Help
By Joseph Osborne

BloodThinnerHelp.com reports on a Madison County lawsuit which was filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson). The suit alleges that the blood thinner, which is meant to prevent strokes, caused the plaintiff’s uncontrollable bleeding episode. After its initial filing, the case was moved during a Xarelto lawsuit consolidation. It was filed as a part of multidistrict litigation (MDL No. 2592) in the Eastern District of Louisiana and is being presided over by the Honorable Judge Eldon E. Fallon.
Xarelto Lawsuit Plaintiff Claims Drug Caused Vermont Man's Fatal Parenchymal Hemorrhage
Jan 11, 2016 | Blood Thinner Help
By Joseph Obrien

BloodThinnerHelp.com reports on the details of a lawsuit filed against manufactureres Janssen Pharmaceuticals and Bayer AG regarding their blood-thinning drug, Xarelto. This suit is just one of many which commonly claim that Xarelto can cause uncontrollable bleeding episodes which can result in severe injury or death.
Xarelto Lawsuit Surge Makes Many Question Blood Thinner's Once-Daily Dosage
Jan 12, 2016 | Blood Thinner Help
By Joseph Osborne

BloodThinnerHelp.com reports on a different lawsuit filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals in Pennsylvania State Court. While many lawsuits have been filed against these manufacturers regarding the dangers of blood thinning drug Xarelto, this one is notable as it brings up new allegations.
Xarelto Lawsuit Bellwether Trial Preparations Underway In Multidistrict Litigation Number 2592
Jan 13, 2016 | Blood Thinner Help
By Joseph Osborne

BloodThinnerHelp.com reports on the progress of nearly 3,000 Xarelto lawsuits which have been consolidated to form a multidistrict litigation group (MDL No. 2592). The lawsuits similarly discuss the medication’s alleged dangerous uncontrollable bleeding side effects, and continue to progress toward trials in the U.S District Court of Eastern Louisiana.
Xarelto Lawsuit Alleges That Drug Manufacturers Are Liable For Wife's Life-Threatening Injuries
Jan 14, 2016 | Blood Thinner Help
By Joseph Osborne

BloodThinnerHelp.com reports on a lawsuit filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson corporation). The lawsuit alleges that their blood thinning drug, Xarelto, caused the wife, an Ohio resident, to suffer from serious and life-threatening bleeding injuries. Together, the husband and wife pair are now requesting in excess of $150,000 in compensation for mounting medical bills, future medical bills, and pain and suffering.
Xarelto Bleeding Lawsuit Cases Consolidated By JPML Under U.S. District Judge Eldon Fallon
Jan 14, 2016 | Blood Thinner Helo
By Joseph Osborne

BloodThinnerHelp.com reports on the U.S. Judicial Panel on Multidistrict Litigation’s consolidation and centralization of all Xarelto bleeding lawsuits filed in federal courts from across the nation. These cases are officially being overseen by the Honorable U.S. District Judge Eldon E. Fallon in the Eastern District of Louisiana. This consolidation was issued on December 12, 2015, and spurred a transfer of all federally-filed cases.

Plaintiff Attorney Blog Posts

Xarelto Court Enters New Case Management Orders
Jan 8, 2016 | Mass Tort Law Blog
By Matthew H. Taylor

Xarelto (rivaroxaban) is a blood thinner that was approved by the U.S. Food & Drug Administration (FDA) in July 2011 to prevent strokes in patients who received hip and knee replacements. In November 2011, the approval was expanded to any patients with atrial fibrillation (irregular heartbeat). Xarelto has been widely prescribed, with millions of people taking the medication since it entered the market.
Xarelto Lawsuit Says Man Suffered Gastrointestinal Bleeding Event
Jan 8, 2016 | Top Class Actions
By Paul Tassin

A Mississippi woman has filed a Xarelto lawsuit, alleging that the blood thinner caused her to suffer a serious gastrointestinal bleeding event. Plaintiff Kimberly A. says she took Xarelto from July 2013 to October 2014 and that after she started taking Xarelto she suffered a serious bleeding complication in her intestines.
New Xarelto Bleeding Lawsuit Filed in Federal Court
Jan 12, 2016 | Top Class Actions
By Laura Schultz

A new Xarelto lawsuit was filed against Janssen Research & Development LLC, a subsidiary of Johnson & Johnson, and Bayer Pharmaceuticals. The Xarelto lawsuit is a part of the multidistrict litigation involving the blood-thinning medication that is before the U.S. District Judge Fallon.
Xarelto Lawsuit Filed Over Injuries From Intracranial Bleeding
Jan 12, 2016 | AboutLawsuits.com
By Irvin Jackson

According to allegations raised in a recent lawsuit filed by a Georgia man, side effects of Xarelto caused him to suffer uncontrollable intracranial bleeding, which have left him with permanent injuries.
Federal Xarelto Bleeding Litigation Moves Forward with Bellwether Trial Selection
Jan 12, 2016 | Bernstein Liebhard LLP

The federal court overseeing thousands of Xarelto bleeding lawsuits has begun the process of selecting cases for its first bellwether trials, which are scheduled to get underway next year. Those trials could provide valuable insight into how juries might decide many of the other Xarelto claims now centralized in the U.S. District Court, Eastern District of Louisiana.
Xarelto Lawsuits Increase, Manufacturers Deny Claims
Jan 12, 2016 | Meyerkord & Meyerkord

Xarelto lawsuits continue to be filed against the drug’s manufacturers, Bayer and Johnson & Johnson. Plaintiffs are claiming that they, or a loved one, has suffered injuries or even death because Bayer and J & J failed to properly warn users regarding the risks of the drug. Xarelto is considered a new type of blood thinner and is being highly promoted as a more convenient option compared to older anticoagulants. Warfarin is a blood thinner that has been on the market for several years prior to Xarelto’s approval. Users that are prescribed Warfarin must restrict their diets and undergo regular blood monitoring. Xarelto users are not required to change any aspects of their lives. With the information advertised by Bayer, Xarelto does appear to be the most convenient choice for a blood thinner. However, what Bayer is failing to tell users is that there is no antidote to reverse the effects of Xarelto causing uncontrollable bleeding. Thousands of lawsuits have now been filed claiming Bayer is responsible for failing to inform patients.
Georgia Xarelto Brain Bleeding Lawsuit
Jan 13, 2016 | The Legal Examiner
By Shezad Malik MD JD

Oren Fells from Georgia recently filed a Xarelto uncontrollable intracranial or brain bleeding lawsuit in the U.S. District Court for the Eastern District of Louisiana. The lawsuit was filed against Bayer Healthcare, Johnson & Johnson, and its Janssen subsidiary, the manufacturers of Xarelto.
Xarelto Lawsuits Rise as First Bellwether Cases Are Selected
Jan 8, 2016 | Legal Bay LLC

Legal-Bay LLC, The Lawsuit Settlement Funding Company, reports today that the court has started the process of selecting 40 cases for the Xarelto multidistrict litigation bellwether trial pool. The Xarelto MDL is underway is the U.S. District Court in the Eastern District of Louisiana. An order datedDecember 17th instructed the plaintiffs and defense to each select 10 cases for the pool by January 11th, of which five were to have originated in the Eastern District of Louisiana, one was to be from Mississippi, one from Texas, and the other three cases were to be from other states.
Three Months After Taking Xarelto, Plaintiff’s Grandmother Was Dead
Jan 13, 2016 | LawyersAndSettlements.com
By Gordon Gibb

Ashlie Fluitt’s beloved grandmother Hattie Deville-Goodwin was prescribed Xarelto for treatment of deep vein thrombosis in her leg. Deep vein thrombosis, commonly known in layman’s terms as a blood clot, is in itself a serious condition and is usually treated through the employment of blood thinners. However, the choice of blood thinner in this case may have hastened Hattie’s demise: within three months Hattie was dead, allegedly from a Xarelto Bleeding Issue.
Xarelto Lawsuit: Blood Thinner Caused Gastrointestinal Bleed
Jan 14, 2016 | Top Class Actions
By Melissa LaFreniere

A New York man has joined the multidistrict litigation against manufacturers of the blood thinner medication Xarelto after allegedly suffering from a gastrointestinal bleed.
Ten People File Lawsuit Over Xarelto Bleeding Risks
Jan 14, 2016 | Righting Injustice
By Jennifer-Walker Journey

Ten individuals from various states have teamed up in a lawsuit against Bayer Healthcare and Johnson & Johnson subsidiary Janssen Pharmaceuticals claiming the drug companies oversold the effectiveness of their blood thinner Xarelto.
Xarelto Lawsuit BMJ Study Notes Potential Twofold Increased Risk Of GI Bleed
Jan 15, 2016 | Blood Thinner Help
By Joseph Osborne

BloodThinnerHelp.com reports on summer studies which link blood thinning drug Xarelto to dangerous bleeding events, such as spontaneous vitreous hemorrhages and gastroinstestinal bleeds. As Xarelto lawsuit numbers continue to grow, and focus turns to the current multidistrict litigation which has consolidated them, many are beginning to discuss the serious side effects which have become linked to the drug. Plaintiffs involved in the lawsuits point to studies from the summer of 2015 which highlight some concerning information.

Full Text of Articles Below

Client Attorney Privileged/Attorney Work Product/At Request of Counsel

Plaintiff Attorney Press Releases

90-Count Xarelto Lawsuit Requests $4.35 Million In Compensation For Alleged Bleeding Events

Jan 8, 2016 | Blood Thinner Help

By Joseph Osborne

BloodThinnerHelp.com reports on a Madison County lawsuit which was filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson). The suit alleges that the blood thinner, which is meant to prevent strokes, caused the plaintiff’s uncontrollable bleeding episode. After its initial filing, the case was moved during a Xarelto lawsuit consolidation. It was filed as a part of multidistrict litigation (MDL No. 2592) in the Eastern District of Louisiana and is being presided over by the Honorable Judge Eldon E. Fallon.
This particular case is a 90-count one, which seeks 4.35 million dollars in compensation. In details of the complaint, the plaintiff notes that defendants misleadingly marketed Xarelto as a safe and effective treatment for individuals who wish to reduce their risk of systemic embolism or stroke. The drug was approved for this use by the U.S. Food and Drug Administration, and was released for sale across the United States in 2011.
According to the plaintiff, manufacturers quickly became aware that bleeding from multiple areas of the body was reportedly increased for those taking the medication, yet, she claims, they did nothing with this knowledge. Her complaint notes: “Defendants use the results of the Rocket AF study, the Record studies, and the Einstein studies to promote Xarelto in their promotional materials, including the Xarelto website, which tout the positive results of those studies. However, defendants’ promotional materials fail to similarly highlight the increased risk of gastrointestinal bleeding and bleeding that required transfusion among other serious bleeding concerns.”
It was alleged that manufacturers spent over $11 million to promote their anticoagulant, which brought them around $582 million in sales the first year, according to the plaintiff. She states that they were misleading by purposefully emphasizing the effectiveness and benefits of the blood thinner, while concealing its dangerous potential side effects.
Unfortunately, the woman is not alone in her claims. Federal court has now reportedly consolidated more than 2,800 lawsuits filed against the drug in the Eastern Louisiana multidistrict litigation group. Additionally, another 500 Xarelto lawsuits have formed a mass tort litigation group in Philadelphia, Pennsylvania’s Court of Common Pleas.
Today, Attorney Joseph Osborne is attempting to ensure that everyone who has used Xarelto and has since suffered from adverse health events may have the opportunity to investigate their legal rights. It is likely that additional cases will be able to join the current MDL as these cases await trial. Attorney Osborne is offering free Xarelto consultations for affected individuals, who may be entitled to compensation.
To ask questions or request additional Xarelto lawsuit information, please contact Attorney Osborne by calling (866) 425-8902.
https://www.pressadvantage.com/story/7049-90-count-xarelto-lawsuit-requests-4-35-million-in-compensation-for-alleged-bleeding-events

Return to headline | Return to top
Xarelto Lawsuit Plaintiff Claims Drug Caused Vermont Man's Fatal Parenchymal Hemorrhage

Jan 11, 2016 | Blood Thinner Help

By Joseph Obrien

BloodThinnerHelp.com reports on the details of a lawsuit filed against manufacturers Janssen Pharmaceuticals and Bayer AG regarding their blood-thinning drug, Xarelto. This suit is just one of many which commonly claim that Xarelto can cause uncontrollable bleeding episodes which can result in severe injury or death.
The suit was filed in Vermont federal court under case number 2:14-cv-00159-cr on July 25th of 2014. It was filed by a daughter on behalf of her father, who died after suffering a parenchymal hemorrhage which his family claims was caused by the Xarelto prescription he was taking at the time of his death. A parenchymal hemorrhage is a brain bleed. Because Xarelto thins the blood, physicians were unable to clot the man’s bleed or prevent him from losing too much blood.
Because Xarelto was released to the market with no corresponding antidote, physicians were unable to counter its effects in this emergency situation. Traditional blood thinners do not pose this issue, as they have an available antidote in vitamin K. When patients with traditional blood thinners in their system begin to bleed, doctors are able to reverse the effects of the blood thinner by treating them with vitamin K, thus clotting their blood. This antidote can be the difference between life and death for patients with even seemingly minor bleeding injuries.
Xarelto is currently the subject of over 2,800 federal court lawsuits, as well as another 500 cases in a mass tort grouping in Philadelphia, PA. The federal court cases have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL number 2592. They currently await legal proceedings.
Attorney Joseph Osborne is working to ensure that anyone who has suffered from adverse health events after using Xarelto will have the opportunity to explore their legal rights. These individuals may be entitled to legal action and significant compensation. Currently, Attorney Osborne is offering free consultations to affected individuals.
To ask questions regarding Xarelto lawsuits or obtain additional information, please contact Joseph Osborne, Esq. at (866) 425-8902.
http://www.wandtv.com/story/30937494/xarelto-lawsuit-plaintiff-claims-drug-caused-vermont-mans-fatal-parenchymal-hemorrhage

Return to headline | Return to top
Xarelto Lawsuit Surge Makes Many Question Blood Thinner's Once-Daily Dosage

Jan 12, 2016 | Blood Thinner Help

By Joseph Osborne

BloodThinnerHelp.com reports on a different lawsuit filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals in Pennsylvania State Court. While many lawsuits have been filed against these manufacturers regarding the dangers of blood thinning drug Xarelto, this one is notable as it brings up new allegations.
Complaints found within the suit state that the drug’s recommended once-daily dosage is not effective for a full 24-hour time period as indicated. Further details of the suit indicate that the plaintiff suffered from a stroke just four days after beginning to take Xarelto in order to prevent strokes. He was at an increased risk of stroke due to his atrial fibrillation condition.
Xarelto is the first and only blood thinner to offer one pill a day, one-size-fits-all dosing. Other blood thinners require 2 doses of medication each day. After suffering from a stroke, the plaintiff in this particular case filed suit on October 8th of 2015 against the drug manufacturers. His atrial fibrillation, a fairly common heart condition, put him at greater risk for stroke so he was prescribed Xarelto as a preventative measure.
The man’s complaint is the first of its kind, despite the fact that Xarelto has been the topic of an ever-increasing number of lawsuits. Other lawsuits, allege that Xarelto causes increased risk for dangerous uncontrollable bleeding episodes and even death. In this particular suit, however, the plaintiff clearly states that Xarelto proved ineffective in preventing his stroke and may have actually been the cause of it.
Across the U.S., Xarelto has been involved in more than 2,800 lawsuits in federal court as well as over 550 suits in a mass tort group in Philadelphia, Pennsylvania. The drug was approved by the U.S. Food and Drug Administration in 2011 to prevent strokes and blood clots for individuals with atrial fibrillation, as well as those recovering from hip and knee replacement surgeries. Consumers were initially enticed to use Xarelto due to the fact that the drug was much more liberating than traditional blood thinners because didn’t require special diets or regular monitoring by a physician.
One major problem with the revolutionary new blood thinner, however, was that it was released to the market without any corresponding antidote. This simply means that patients with Xarelto in their system who begin to bleed will be unable to get their blood to clot. In these circumstances, the physicians treating these patients are are required to resort to life-saving measures such as blood transfusions.
Traditional blood thinners do not have this issue, which is why they require special diets. They have an available antidote in vitamin K, which means their effects are able to be reversed with vitamin K treatments. If someone using a traditional blood thinner begins to bleed, doctors can treat them with vitamin K and their blood will clot, a potential life-and-death difference in emergency situations.
Federally filed Xarelto lawsuits have been consolidated to form multidistrict litigation number 2592 and are being overseen by the Honorable U.S. District Judge Eldon E. Fallon. As the cases in the MDL await trial, Attorney Joseph Osborne is working to help ensure that anyone suffering after using Xarelto will have the opportunity to explore their legal rights. He offers free consultations to those involved, who may be entitled to significant compensation.
To ask questions, or request additional information on Xarelto lawsuits, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.wrcbtv.com/story/30946558/xarelto-lawsuit-surge-makes-many-question-blood-thinners-once-daily-dosage

Return to headline | Return to top
Xarelto Lawsuit Bellwether Trial Preparations Underway In Multidistrict Litigation Number 2592

Jan 13, 2016 | Blood Thinner Help

By Joseph Osborne

BloodThinnerHelp.com reports on the progress of nearly 3,000 Xarelto lawsuits which have been consolidated to form a multidistrict litigation group (MDL No. 2592). The lawsuits similarly discuss the medication’s alleged dangerous uncontrollable bleeding side effects, and continue to progress toward trials in the U.S District Court of Eastern Louisiana.
According to a court order from December 17th, 2015, the process of selecting 40 cases from the MDL to form a bellwether trial pool has now begun. The order required that both plaintiffs and defendants were to each select 10 cases for the pool by Monday, January 11th, 2016. The cases were to be from four previously specified locations, including Eastern Louisiana, where the MDL is being housed. Additionally, they were expected to meet certain criteria, to provide a variety for future bellwether case selections.
Criteria requested was that lawsuits should involve: someone who had suffered a gastrointestinal bleed, someone who suffered a brain hemorrhage, and someone who suffered from rectal bleeding, all while using Xarelto in order to prevent a stroke. Additionally, it was requested that certain lawsuits selected also involve patients who suffered gastrointestinal bleeds, brain hemorrhages, or rectal bleeding while using the drug to treat pulmonary embolism or deep vein thrombosis (DVT).
It was noted that by January 15th of 2016, the court would select an additional 20 lawsuits at random to join 10 selected by the plaintiffs and 10 selected by the defendants, creating the bellwether trial pool of 40. The 20 cases selected by the court will include lawsuits from Louisiana and Mississippi, as well as one from each of a total of eight other states which will be selected by the parties involved.
Due to the sheer volume of Xarelto bleeding lawsuits which are being filed against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson), many expect that others will continue to be filed, and that these cases may be able to join those involved in the current MDL. For those wishing to explore this process, Attorney Joseph Osborne is currently offering free legal consultations to anyone who used Xarelto and suffered from adverse health events. These individuals may be entitled to legal action and significant compensation.
http://www.cbs19.tv/story/30962091/xarelto-lawsuit-bellwether-trial-preparations-underway-in-multidistrict-litigation-number-2592

Return to headline | Return to top
Xarelto Lawsuit Alleges That Drug Manufacturers Are Liable For Wife's Life-Threatening Injuries

Jan 14, 2016 | Blood Thinner Help

By Joseph Osborne

BloodThinnerHelp.com reports on a lawsuit filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson corporation). The lawsuit alleges that their blood thinning drug, Xarelto, caused the wife, an Ohio resident, to suffer from serious and life-threatening bleeding injuries. Together, the husband and wife pair are now requesting in excess of $150,000 in compensation for mounting medical bills, future medical bills, and pain and suffering.
Details found within the court documents indicate that the plaintiff involved was prescribed Xarelto (rivaroxaban) by her family physician in order to treat a common heart condition known as atrial fibrillation which can cause strokes. The medication was taken as a preventative measure to avoid these strokes, however, the couple states, the wife ended up suffering from something just as serious.
Just two months after beginning to use Xarelto, the woman suddenly suffered from severe gastrointestinal bleeding, and anemia, as well as multiple other injuries that were not detailed but are said to be long-lasting health problems. Still today, the woman requires medical treatments and says that she is no longer able to enjoy life as she used to.
Xarelto was approved by the U.S. Food and Drug Administration as a new type of anticoagulant. It was intended to help reduce the risk of blood clots for individuals recovering from hip and knee replacement surgeries, as well as reducing the risk of stroke for those with atrial fibrillation.
After its initial market launch, Xarelto has quickly become the topic of almost 3,000 lawsuits filed across the United States, which commonly allege that the drug causes patients an increased risk of uncontrollable bleeding episodes, some of which could prove fatal.
Federally filed Xarelto lawsuits have been consolidated by the JPML to form multidistrict litigation number 2592. They are being overseen in the Eastern District of Louisiana. This case, as well, is expected be transferred there for pretrial proceedings.
As these cases await trial, many anticipate that others will continue to join them. Attorney Joseph Osborne is now working to help anyone who may have been negatively affected by Xarelto but who has not yet filed a lawsuit. These individuals may be entitled to legal action and substantial compensation. Those involved are encouraged to fully explore their legal options, and are currently offered free consultations by Attorney Osborne.
To request further information or ask questions, please contact Joseph Osborne, Esq., by calling (866) 425-8902.
http://www.kusi.com/story/30962089/xarelto-lawsuit-alleges-that-drug-manufacturers-are-liable-for-wifes-life-threatening-injuries

Return to headline | Return to top
Xarelto Bleeding Lawsuit Cases Consolidated By JPML Under U.S. District Judge Eldon Fallon

Jan 14, 2016 | Blood Thinner Helo

By Joseph Osborne

BloodThinnerHelp.com reports on the U.S. Judicial Panel on Multidistrict Litigation’s consolidation and centralization of all Xarelto bleeding lawsuits filed in federal courts from across the nation. These cases are officially being overseen by the Honorable U.S. District Judge Eldon E. Fallon in the Eastern District of Louisiana. This consolidation was issued on December 12, 2015, and spurred a transfer of all federally-filed cases.
Due to the fact that the involved cases were all filed against the same defendants and made strikingly similar allegations, the choice to consolidate was likely an easy one. Consolidation allows those involved to fast track the litigation by avoiding most duplicative discovery regarding common issues, and avoiding conflicting rulings during pretrial by multiple judges. In addition, consolidation is convenient for those involved as it conserves their time and legal expenses.
Xarelto lawsuits consolidated in the MDL are said to number over 2,800. These numbers quickly escalated after the formation of the MDL, and are expected to continue to grow as more people file complaints alleging that they experienced dangerous uncontrollable bleeding episodes while taking the blood thinning drug. Defendants in this MDL are Bayer AG and Janssen Pharmaceuticals, whose parent company is well-known pharmaceutical giant Johnson & Johnson.
The MDL consolidation came in response to a group of plaintiffs’ request, which was submitted in October of 2015, requesting that the JPML centralize the cases. This request initially asked that the cases be housed in the Southern District of Illinois. This request was met with contention by the defendants, which argued that cases should be transferred to New Jersey, due to their location.
After a hearing session which took place December 4th of 2015, the U.S. JPML announced, “In our judgement, the considerable growth in the litigation over the past few months demonstrates that informal coordination is not practical.” Additionally, they noted that they had decided that cases would be presided over by Judge Eldon Fallon, explaining, “Judge Eldon E. Fallon, who presides over three potential tag-along (Xarelto) actions, is an experienced transferee judge with the willingness and ability to manage this litigation efficiently. He is well-versed in multidistrict litigation, and we are confident he will steer this matter on a prudent course.”
As the cases involved in this MDL (no.2592) await trial, it is expected that their numbers will only continue to grow. Attorney Joseph Osborne is working to ensure that in the meantime, others who have suffered due to taking Xarelto who have not yet filed will have the opportunity to explore their legal rights in the matter. He is offering free legal consultations to involved individuals at this time, who may be entitled to significant compensation.
To request additional information on Xarelto bleeding lawsuits, or to ask questions at any time, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2802997#ixzz3xKQJVVVe

Return to headline | Return to top

Plaintiff Attorney Blog Posts

Xarelto Court Enters New Case Management Orders

Jan 8, 2016 | Mass Tort Law Blog

By Matthew H. Taylor

Xarelto (rivaroxaban) is a blood thinner that was approved by the U.S. Food & Drug Administration (FDA) in July 2011 to prevent strokes in patients who received hip and knee replacements. In November 2011, the approval was expanded to any patients with atrial fibrillation (irregular heartbeat). Xarelto has been widely prescribed, with millions of people taking the medication since it entered the market.
The number of lawsuits alleging injuries associated with ingestion of Xarelto continues to grow in the United States. Many of the pending lawsuits are centralized in federal court before the Honorable Eldon E. Fallon, in the Eastern District of Louisiana (“EDLA”), as part of MDL 2592. As we have previously reported, Judge Fallon has entered a series of Case Management Orders that continue to maximize the efficient management of the litigation.
On November 20, 2015, the EDLA issued Case Management Order #3, setting forth the general criteria for selecting the 40 discovery pool plaintiffs. These plaintiffs are jointly selected by the plaintiffs and defendants’ attorneys, for purposes of trial preparation.
On December 17, 2015, the EDLA issue Case Management Order #4, which provided more detailed instruction on the selection of the 40 discovery pool plaintiffs. The Order provides for
The selection of discovery pool plaintiffs;
The eligibility criteria of discovery pool plaintiffs; and,
The categories of discovery pool plaintiffs.
For example, to be eligible for the discovery pool, a plaintiff must satisfy the criteria in one of the following categories: a) plaintiff, between the ages of 50 and 90, must have taken Xarelto to reduce the risk of stroke and systemic embolism due to nonvalvular atrial fibrillation and allege a gastrointestinal bleed or death; or b) plaintiff, between the ages of 40 and 80, must have taken Xarelto to treat deep vein thrombosis or pulmonary embolism and allege a gastrointestinal bleed or death; or c) plaintiff, between the ages of 50 and 90, must have taken Xarelto to reduce the risk of stroke and systemic embolism due to nonvalvular atrial fibrillation and allege rectal bleeding or death; or d) plaintiff, between the ages of 40 and 80, must have taken Xarelto to treat deep vein thrombosis or pulmonary embolism and allege rectal bleeding or death; or e) plaintiff, between the ages of 50 and 90, must have taken Xarelto to reduce the risk of stroke and systemic embolism due to nonvalvular atrial fibrillation and allege a brain bleed/hemorrhagic stroke or death; or f) plaintiff, between the ages of 40 and 80, must have taken Xarelto to treat deep vein thrombosis or pulmonary embolism and allege a brain bleed/hemorrhagic stroke or death.Xarelto Litigation
The attorneys at Stark & Stark continue to pursue all legal redress available in the federal action, as well as state actions in Pennsylvania and New Jersey, for the benefit of its clients that have suffered injuries resulting from their use of Xarelto.

Return to headline | Return to top
Xarelto Lawsuit Says Man Suffered Gastrointestinal Bleeding Event

Jan 8, 2016 | Top Class Actions

By Paul Tassin

A Mississippi woman has filed a Xarelto lawsuit, alleging that the blood thinner caused her to suffer a serious gastrointestinal bleeding event.
Plaintiff Kimberly A. says she took Xarelto from July 2013 to October 2014 and that after she started taking Xarelto she suffered a serious bleeding complication in her intestines.
Kimberly now attributes that gastrointestinal bleed to the Xarelto she took around that time.
Janssen Pharmaceuticals Inc., its parent company Johnson & Johnson Co., Bayer Healthcare Pharmaceuticals Inc., and their related companies are all named as defendants in the Xarelto lawsuit. Kimberly alleges that all these companies had a hand in the development, manufacturing, marketing or distribution of Xarelto.
Also known by its generic name rivaroxaban, Xarelto is among the new generation of anticoagulant medications introduced just within the last few years.
Before these new generation blood thinners appeared, Warfarin had been the go-to blood thinner for several decades.
Xarelto’s manufacturers promoted the new drug as having certain advantages over Warfarin, such as a once-a-day dosing schedule and no need for continuous blood tests.
Xarelto Clinical Trials
Kimberly cites one clinical study in particular, the ROCKET AF study, that had been part of the basis for the Food and Drug Administration’s (FDA) approval of Xarelto as treatment to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation.
While the ROCKET AF study found that Xarelto was “non-inferior” to Warfarin when used for that purpose, it also found that gastrointestinal bleeds occurred more frequently in patients who used Xarelto than in those who used Warfarin.
The Xarelto bleeding lawsuit accuses the defendants of cherry-picking information from the ROCKET AF and other studies in developing their promotional materials for Xarelto. She says those promotional materials failed to mention the risk of gastrointestinal bleeds and other adverse events revealed by those studies.
Kimberly also challenges the defendants’ marketing of Xarelto as not needing regular blood monitoring. The defendants had asserted this point as an advantage Xarelto had over Warfarin, which requires regular blood testing and dosage adjustment to keep the dosage correct.
Kimberly says in her Xarelto lawsuit that the results of the clinical trials showed that Xarelto was safer when administered in conjunction with regular blood monitoring.
Likewise, Kimberly challenges the manufacturers’ once-daily dosing scheme. She cites comments attributed to FDA reviewers who questioned that dosing scheme, noting that blood level studies showed peaks and dips that the reviewers said could have been eliminated by twice-daily dosing.
Kimberly argues that encouraging taking Xarelto on a once-daily dosing schedule and without ongoing blood monitoring increases the risk of major, life-threatening Xarelto bleeding events like the one she suffered.
Kimberly also notes that at the end of fiscal 2012, Xarelto’s first year on the market, the FDA received 2,081 reports of serious adverse events associated with Xarelto. Of these events, 151 reportedly resulted in the patient’s death.
Similar reports arose in Germany. The Xarelto lawsuit states that in the first eight months of 2013, German regulators received 968 reports of adverse events related to Xarelto, 72 of which resulted in death.
Kimberly says the defendants neither alerted the public or the medical community about these reports, nor did they perform any additional investigations into the safety of Xarelto.
Kimberly’s individual Xarelto lawsuit is part of the Xarelto multidistrict litigation centralized in Louisiana.
The Xarelto Multidistrict Litigation is In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL No. 2592 in the U.S. District Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/279693-plaintiff-from-mississippi-joins-xarelto-multidistrict-litigation/

Return to headline | Return to top
New Xarelto Bleeding Lawsuit Filed in Federal Court

Jan 12, 2016 | Top Class Actions

By Laura Schultz

A new Xarelto lawsuit was filed against Janssen Research & Development LLC, a subsidiary of Johnson & Johnson, and Bayer Pharmaceuticals.
The Xarelto lawsuit is a part of the multidistrict litigation involving the blood-thinning medication that is before the U.S. District Judge Fallon.
According to the Xarelto lawsuit, Plaintiff Gerald F., a resident of Travis County Texas began taking Xarelto in November of 2013 as prescribed by his physician. He continued to take the anticoagulant drug until July of 2014.
Gerald alleges that as a direct result of taking Xarelto he suffered melena, or bloody stool, in November of 2013 and a gastrointestinal bleed in February of 2014. Due to the gastrointestinal bleeding, Gerald was hospitalized for 3 days and received transfusions of four units of red blood cells.
The Xarelto injury lawsuit alleges that the defendants failed to warn the medical community and the general public about dangerous side effects associated with taking Xarelto. Additionally, Gerald alleges that as part of its marketing scheme, Xarelto marketers participated in direct to consumer advertising campaigns that were designed to influence patients to ask for Xarelto above other blood thinning medications.
According to Gerald’s complaint, Xarelto advertised itself as a superior alternative to the more traditional blood thinner warfarin. It is alleged that Xarelto was advertised to not require any blood monitoring, but the lawsuit suggests that studies show without appropriate blood monitoring, dose adjustment, and twice a day dosing patients are at risk of major life-threatening bleeding events.
About Xarelto
Xarelto is a popular blood thinning medication that was introduced to the US market in July of 2011. It was approved to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, to treat deep vein thrombosis and pulmonary embolism, and to prevent these conditions in patients undergoing hip or knee replacement surgery.
Xarelto along with other oral anticoagulants in its class were introduced as a replacement for warfarin which requires patients follow dietary restrictions and undergo constant blood monitoring.
According to the FDA adverse event reports, Xarelto patients reported 680 adverse events reports submitted with its competitor Pradaxa following with 528. Prior to Xarelto’s release, Pradaxa had been ranked number one in the quantity of FDA-reported adverse events.
Xarelto Lawsuits
Product liability attorneys are currently looking for potential plaintiffs to bring Xarelto lawsuits against the pharmaceutical manufacturers. These lawsuits will likely allege that the companies violated consumer protection laws. Successful plaintiffs will likely receive monetary compensation for their past medication bills and the pain and suffering they experienced due to taking the medication.
The Xarelto Lawsuit is Case No. 2:15-cv-05978-EEF-MBN in the US District Court in the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/263081-new-xarelto-lawsuit-filed-in-federal-court/

Return to headline | Return to top
Xarelto Lawsuit Filed Over Injuries From Intracranial Bleeding

Jan 12, 2016 | AboutLawsuits.com

By Irvin Jackson

According to allegations raised in a recent lawsuit filed by a Georgia man, side effects of Xarelto caused him to suffer uncontrollable intracranial bleeding, which have left him with permanent injuries.
The complaint (PDF) was filed by Oren Fells in the U.S. District Court for the Eastern District of Louisiana on January 9, naming Bayer Healthcare, Johnson & Johnson, and its Janssen subsidiary, as defendants.
According to allegations raised in the lawsuit, Fells suffered an intracranial bleed from Xarelto, which was life-threatening and which physicians were hard-pressed to stop.
Fells began taking the new-generation anticoagulant Xarelto in August 2013, for the treatment of atrial fibrillation. The brain bleed began on January 11, 2014, causing him to suffer severe pain and suffering, mental anguish, diminished enjoyment of life, medical expenses, loss of earnings and permanent injuries that will continue to impact him throughout the remainder of his life.
The case joins a growing number of similar Xarelto lawsuits, which allege that the drug makers knew about the risk of uncontrollable bleeding, yet failed to warn consumers or the medical community
“Defendants concealed their knowledge of Xarelto’s defects from Plaintiff, the FDA, the public in general and/or the medical community specifically,” the Fells states in his complaint. “Defendants negligently and improperly failed to perform sufficient tests, if any, on humans using Xarelto during clinical trials, forcing Plaintiff, and Plaintiff’s physicians, hospitals, and/or the FDA, to rely on safety information that applies to other non-valvular and fibrillation treatment and DVT/PE (deep vein thrombosis/pulmonary embolism) treatment and prophylaxis, which does not entirely and/or necessarily apply to Xarelto whatsoever.”
Xarelto Bleeding Litigation
Xarelto (rivaroxoaban) was introduced in 2011 as a replacement for Coumadin (warfarin), which has been the go-to anticoagulant treatment for decades. The drug is part of a new-generation of blood thinners, which have been promoted as easier to use than warfarin, the go-to anticoagulation treatment for decades. However, a large number of Xarelto bleeding problems have been reported since the drug hit the market.
There are currently at least 2,400 complaints filed throughout the federal court system, each involving allegations that Xarelto caused individuals to suffer bleeding injuries.
The Xarelto litigation is currently centralized before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana for coordinated discovery and pretrial proceedings, and it is expected that Fells’ lawsuit will be transferred in the federal MDL, or multidistrict litigation.
As part of the coordinated proceedings before Judge Fallon, the parties are currently engaged in generic discovery into issues that apply to all claims, but are also working to identify a small group of bellwether cases that will go through case-specific discovery and be eligible for early test trials, to help gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout the litigation.
Similar claims were raised in litigation over Pradaxa, which is another new-generation anticoagulant introduced in October 2010, one year before Xarelto hit the market.
More than 4,000 Pradaxa lawsuits were ultimately filed by users of that drug who suffered bleeding injuries. Following several years of litigation, the manufacturer of that medication ultimately agreed to pay $650 million in Pradaxa settlements, with an average of about $150,000 per claim.
As Xarelto bleeding lawyers continue to review potential cases for individuals prescribed the anticoagulant throughout the United States, it is expected that this litigation will involve many more cases than the Pradaxa litigation, as the drug has become more widely used in recent years.
http://www.aboutlawsuits.com/xarelto-brain-bleed-lawsuit-92614/#sthash.9Gaz9PqT.dpuf

Return to headline | Return to top
Federal Xarelto Bleeding Litigation Moves Forward with Bellwether Trial Selection

Jan 12, 2016 | Bernstein Liebhard LLP

The federal court overseeing thousands of Xarelto bleeding lawsuits has begun the process of selecting cases for its first bellwether trials, which are scheduled to get underway next year. Those trials could provide valuable insight into how juries might decide many of the other Xarelto claims now centralized in the U.S. District Court, Eastern District of Louisiana.
The Court had earlier indicated that it planned to convene four bellwether trials, starting in February 2017. The first two trials will be heard in the Eastern District of Louisiana, while the third and fourth will be convened in yet-to-named U.S. District Courts in Texas and Mississippi. The cases going before juries are to be selected from a pool of 40 Xarelto lawsuits, 20 of which were to be chosen by the parties and the remaining 20 by the Court.
Xarelto Bellwether Trial Pool
On December 17, 2015, the Court issued an Order directing the parties to each submit 10 bellwether trial candidates by January 11th. Five of those lawsuits must have originated in the Eastern District of Louisiana, one from Mississippi, one from Texas and three cases from other states. Though they are not required to do so, the Order asks that the parties “endeavor” to choose at least one case from each of the following injury categories:
Gastrointestinal bleeding cases: 1 involving a patient prescribed Xarelto to prevent stroke, and 1 involving a patient who took the drug to treat pulmonary embolism and/or deep vein thrombosis.
Brain bleeding cases: 1 involving a patient prescribed Xarelto to prevent stroke, and 1 involving a patient who took the drug to treat pulmonary embolism and/or deep vein thrombosis.
Rectal bleeding cases: 1 involving a patient prescribed Xarelto to prevent stroke, and 1 involving a patient who took the drug to treat pulmonary embolism and/or deep vein thrombosis.
By January 15th, the Court will randomly select 20 additional Xarelto lawsuits for the bellwether trial pool.
Xarelto Allegations
Court records indicate that at least 2,400 Xarelto lawsuits are now pending in the multidistrict litigation underway in Louisiana. All of the plaintiffs involved in the proceeding are alleged to have suffered dangerous episodes of uncontrollable bleeding due to their use of the novel anticoagulant. Among other thing, the lawsuits allege that the drug’s manufacturers wrongly marketed Xarelto as a superior alternative to warfarin, a much older blood thinning medication. Among other things, they point out that internal hemorrhaging associated with warfarin can be stopped via the administration of vitamin K. However, there currently exists no approved antidote to reverse Xarelto bleeding.
If you or a loved one experienced a life-threatening episode of internal bleeding while taking Xarelto, legal help is available. To arrange for a free legal review of your case, please contact Bernstein Liebhard LLP by call 1-877-779-1414.
http://www.consumerinjurylawyers.com/xarelto-bleeding-lawsuit-court-moves-forward-with-bellwether-trial-selection#sthash.bV1yM2p4.dpuf

Return to headline | Return to top
Xarelto Lawsuits Increase, Manufacturers Deny Claims

Jan 12, 2016 | Meyerkord & Meyerkord

Xarelto lawsuits continue to be filed against the drug’s manufacturers, Bayer and Johnson & Johnson. Plaintiffs are claiming that they, or a loved one, has suffered injuries or even death because Bayer and J & J failed to properly warn users regarding the risks of the drug. Xarelto is considered a new type of blood thinner and is being highly promoted as a more convenient option compared to older anticoagulants. Warfarin is a blood thinner that has been on the market for several years prior to Xarelto’s approval. Users that are prescribed Warfarin must restrict their diets and undergo regular blood monitoring. Xarelto users are not required to change any aspects of their lives. With the information advertised by Bayer, Xarelto does appear to be the most convenient choice for a blood thinner. However, what Bayer is failing to tell users is that there is no antidote to reverse the effects of Xarelto causing uncontrollable bleeding. Thousands of lawsuits have now been filed claiming Bayer is responsible for failing to inform patients.
Contact our Xarelto lawsuit attorneys if you have experienced any of the following injuries while using Xarelto:
Gastrointestinal bleeding
Brain Bleed
Rectal Bleeding
Uncontrollable Bleeding, or
Death
The drug liability attorneys at Meyerkord & Meyerkord, LLC have fought to hold numerous drug manufacturers responsible for producing dangerous drugs. We have the experience necessary to successfully handle your case and obtain the compensation you deserve for your damages. If you have been the victim of an unsafe drug, contact us to receive a free no-obligation consultation.
http://www.stlouis-personalinjury.com/Blog/2016/January/Xarelto-Lawsuits-Increase-Manufacturers-Deny-Cla.aspx

Return to headline | Return to top
Georgia Xarelto Brain Bleeding Lawsuit

Jan 13, 2016 | The Legal Examiner

By Shezad Malik MD JD

Oren Fells from Georgia recently filed a Xarelto uncontrollable intracranial or brain bleeding lawsuit in the U.S. District Court for the Eastern District of Louisiana. The lawsuit was filed against Bayer Healthcare, Johnson & Johnson, and its Janssen subsidiary, the manufacturers of Xarelto.
Catastrophic Xarelto Brain Bleeding Allegations
Fells began taking the newer anticoagulant or blood thinner Xarelto in 2013, for the treatment of atrial fibrillation, a common heart rthym problem. Fells suffered a brain bleed in January, 2014, causing him to develop life long permanent injuries.
Many lawsuits have been filed against Xarelto’s manufacturers, Bayer and Johnson & Johnson and the plaintiffs claim that the companies failed to warn patients and doctors about the risks associated with Xarelto and the lack of an antidote to help stop the bleeding.
What is Xarelto?
Xarelto (rivaroxoaban) was FDA approved in 2011 as an alternative for Coumadin (warfarin), which has been the gold standard anticoagulant treatment for the past 60 years. Xarelto is one of several new-generation blood thinners, which have been promoted as easier to use than warfarin. Unfortunately, several thousand Xarelto bleeding problems have been reported since the medication was used.
Xarelto Federal MDL Litigation
According to the latest federal court census, there are almost 2,500 lawsuits filed, alleging that Xarelto caused patients to develop serious bleeding injuries. The Xarelto litigation is consolidated and centralized before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana as part of Multidistrict litigation (MDL) since December 2014.
Lawsuits against Bayer and Johnson & Johnson are consolidated in two courts, a multidistrict litigation court in the Eastern District of Louisiana and a mass tort litigation court in Philadelphia.
As is common in pharmaceutical multi-district litigation, a small group of Xarelto injury cases are scheduled to go through case-specific discovery and be set for early test trials, these are known as “bellwether trials.”
4 Xarelto Bellwether Trials Set
Judge Fallon set a series of four bellwether trials to go before juries in the Spring of 2017. The number of Xarelto lawsuits continue to increase and be filed by individuals across the United States, alleging severe and deadly bleeding complications.
Bellwether Trials in Louisiana, Mississippi and Texas
The first two trials will be held in the Eastern District of Louisiana, on February 6 and March 13, 2017. The third trial will be held in Mississippi on April 24, 2017 and the fourth trial will be held in Texas on May 30, 2017.
According to Judge Fallon’s order, the cases that will go before juries on these dates will be pulled from a pool of 40 lawsuits to be selected in January 2016. These cases will be trial ready, with case-specific discovery, including depositions of plaintiffs, prescribing doctors, treating physicians and sales representatives of the drug makers.
Pradaxa MDL Settlement
Pradaxa, the first new-generation anticoagulant to hit the market was also exposed to several thousand bleeding complication lawsuits. More than 4,000 Pradaxa injury lawsuits were filed, and Boehringer Ingleheim, the manufacturer agreed to settle the claims without any trials and paid $650 million in Pradaxa settlements, with an average of about $150,000 per claim.
http://fortworth.legalexaminer.com/fda-prescription-drugs/georgia-xarelto-brain-bleeding-lawsuit/

Return to headline | Return to top
Xarelto Lawsuits Rise as First Bellwether Cases Are Selected

Jan 8, 2016 | Legal Bay LLC

Legal-Bay LLC, The Lawsuit Settlement Funding Company, reports today that the court has started the process of selecting 40 cases for the Xarelto multidistrict litigation bellwether trial pool. The Xarelto MDL is underway is the U.S. District Court in the Eastern District of Louisiana. An order datedDecember 17th instructed the plaintiffs and defense to each select 10 cases for the pool by January 11th, of which five were to have originated in the Eastern District of Louisiana, one was to be from Mississippi, one from Texas, and the other three cases were to be from other states.
The court order also asked the parties to try to choose at least one case from six different injury categories. The injury categories include gastrointestinal bleed, brain bleed/hemorrhagic stroke, and rectal bleeding, and the court order is requesting cases for individuals who suffered these injuries while using Xarelto to prevent stroke, as well as individuals who used Xarelto to treat pulmonary embolism or deep vein thrombosis. Documents show that the court will select an additional 20 lawsuits by January 15th, including 10 cases from Louisiana, two cases from Mississippi, and one case each from eight other states. Four bellwether trials are set to begin in February of 2017. The first two trials are set to take place in the Eastern District of Louisiana on February 6th, 2017 and March 13th, 2017. The third and fourth trials will take place in Mississippi and Texas on April 24th, 2017 and May 30th, 2017.
Court records show that approximately 2,400 filed Xarelto cases are pending in the Eastern District of Louisianaagainst Bayer and Johnson & Johnson's subsidiary, Janssen Pharmaceutical Division. The lawsuits include claims of serious health problems, long hospital stays, and even death as a result of uncontrollable bleeding events. According to experts, there is no known antidote at this time.
Chris Janish, CEO of Legal-Bay, commented on the recent announcement in the Xarelto multidistrict litigation, "As we anticipated, the Xarelto litigation is picking up steam, quite possibly faster than we had even imagined. We remain close to this litigation and believe it will continue to be fought hard by the defendant, but with the serious nature of the injuries we are committed to assisting Xarelto patients who believe they were injured due to the drug usage."
In order to receive lawsuit funding you must have retained a Xarelto lawyer first. If you need lawsuit money or pre-settlement funding for your Xarelto claim, Legal-Bay is here to help. Legal-Bay is offering pre-settlement and settlement funding for Xarelto cases as well as other blood thinners – such as Pradaxa – and they are also providing free legal consultations for possible plaintiffs who have not yet retained a Xarelto lawyer. To learn more about Xarelto, Pradaxa, and other blood thinner cases, including services in helping you find a Xarelto lawyer or Xarelto law firm, visit: http://lawsuitssettlementfunding.com/pradaxa-settlement-funding.php
For more information or assistance with finding a qualified Xarelto law firm or Xarelto lawyer, contact Legal-Bay directly at: http://lawsuitssettlementfunding.com/contact-us.php
To speak with a live agent to discuss receiving pre-settlement lawsuit money or a free legal consultation on your potential Xarelto or Pradaxa blood thinner lawsuit, call Legal-Bay's toll-free hotline at: 877.571.0405.
You may also apply online at: http://lawsuitssettlementfunding.com and an agent will respond to your request shortly.
http://www.wtrf.com/story/30955163/xarelto-lawsuits-rise-as-first-bellwether-cases-are-selected

Return to headline | Return to top
Three Months After Taking Xarelto, Plaintiff’s Grandmother Was Dead

Jan 13, 2016 | LawyersAndSettlements.com

By Gordon Gibb

Ashlie Fluitt’s beloved grandmother Hattie Deville-Goodwin was prescribed Xarelto for treatment of deep vein thrombosis in her leg. Deep vein thrombosis, commonly known in layman’s terms as a blood clot, is in itself a serious condition and is usually treated through the employment of blood thinners. However, the choice of blood thinner in this case may have hastened Hattie’s demise: within three months Hattie was dead, allegedly from a Xarelto Bleeding Issue.

Her granddaughter has filed a Xarelto lawsuit, alleging wrongful death. The Case isAshlie Fluitt v. Janssen Research & Development LLC et al, Case No. 2:15-cv-05874, filed November 12 in US District Court, Eastern District of Louisiana.

Xarelto is part of a next-generation series of blood thinners designed to do away with the constant monitoring that is required of the previous gold standard for blood thinners, Coumadin. The latter required constant screening of diet and other factors to ensure all was in balance to ward against a bleeding event. Doctors and their patients have, for years, been pleading for an alternative that required less monitoring.

When Xarelto became available (and Pradaxa before it), the health care community embraced it in droves.

However, the one issue that is serving to fuel the majority of Xarelto lawsuits is the lack of a reversing agent should a Xarelto Bleedout occur. With Coumadin (warfarin), an infusion of vitamin K would quickly act to reverse the thinning properties of blood, helping it to clot more easily and help stem a hemorrhage.

Xarelto was released to the market without benefit of an antidote, and thus without an important implement in the doctor’s tool belt in the event of unforeseen Xarelto bleeding complications.

That’s what happened to Deville-Goodman. After developing a severe Xarelto Bleedout in the brain, her doctors did not have benefit of a vitamin K reversing agent to help stem the bleeding event, and Deville-Goodman died a Xarelto Death.
In her Xarelto Lawsuit, filed in US District Court for the Eastern District of Louisiana, Fluitt accuses Xarelto manufacturers Bayer and Johnson & Johnson (among other defendants) of failure to warn about the risks associated with Xarelto over more traditional anticoagulants like Coumadin.

Previous lawsuits have also asserted that the manufacturers of Xarelto have been irresponsible in marketing Xarelto as not requiring stringent monitoring when - in fact - such monitoring is made all the more feasible and necessary without a ready antidote available.

At the moment, the case load is almost at 3,000, with 2,400 lawsuits consolidated in multidistrict litigation in Louisiana and another 500 state lawsuits within a mass tort in Philadelphia.

Meanwhile, four bellwether lawsuits are scheduled a little more than a year from now, in the spring of 2017.
https://www.lawyersandsettlements.com/articles/xarelto/xarelto-lawsuit-death-bleeding-issue-33-21196.html#.Vpf5Q_krK00

Return to headline | Return to top
Xarelto Lawsuit: Blood Thinner Caused Gastrointestinal Bleed

Jan 14, 2016 | Top Class Actions

By Melissa LaFreniere

A New York man has joined the multidistrict litigation against manufacturers of the blood thinner medication Xarelto after allegedly suffering from a gastrointestinal bleed.
Plaintiff Michael B. filed the Xarelto lawsuit over claims that the anticoagulant that he had only been taking for six months was the cause of his gastrointestinal bleeding event.
Michael alleges that pharmaceutical giants Bayer Healthcare, Johnson & Johnson as well as its subsidiary Janssen Pharmaceuticals failed to include a “boxed warning” about the serious bleeding complications associated with Xarelto. He also claims that the original U.S. Xarelto label did not contain a warning that should a bleeding event occur, there was no reversal agent available.
The Xarelto bleeding lawsuit states that by not including this information to the public, the manufacturers risked the lives of consumers.
“Defendants made conscious decisions not to redesign, re-label, warn or inform the unsuspecting consuming public,” the Xarelto lawsuit states.
Michael alleges that the “outrageous conduct” of Xarelto manufacturers should permit that punitive damages be awarded.
The “Xarelto Difference”
Xarelto was introduced on the U.S. market in 2011 as part of a new class of drugs meant to replace the traditional blood thinner Warfarin (coumadin). Xarelto manufacturers spent millions promoting the new anticoagulant, who’s primary purpose was to reduce the risk of stroke in atrial fibrillation patients and is often prescribed to patients to prevent blood clots after hip or knee surgery.
As part of the marketing of Xarelto, manufacturers promoted the medication as a single, daily dose pill that does not require blood testing or a restricted diet. They labeled this distinction between the old and new blood thinner as the “Xarelto Difference.”
According to the Xarelto lawsuit, manufacturers over-marketed the new medication by widely publicizing through direct-to-consumer advertisements about the safety and efficacy of the blood thinner.
The Xarelto bleeding lawsuit claims that while promoting the anticoagulant, manufacturers “failed to disclose the need for dose adjustments, failed to disclose the need for blood monitoring, and failed to adequately disclose to patients that there is no drug, agent, or means to reverse the anticoagulation effects of Xarelto, and, that such irreversibility could have permanently disabling, life-threatening and fatal consequences.”
Xarelto Bleeding Lawsuits
While the new blood thinner has only been on the U.S. market for a few short years, it has already been named in thousands of FDA adverse event reports, hundreds of which claim the drug caused a hemorrhage-related death.
Last March, an order was issued that made it unnecessary for plaintiffs to have to file a Xarelto lawsuit into a local district to wait to be transferred to the Xarelto MDL centralized in Louisiana.
Those who lost a loved one due to Xarelto bleeding side effects may be able to file a wrongful death lawsuit.
The Xarelto Lawsuit is In re: Xarelto Products Liability Litigation MDL No. 2592 in the U.S. District Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/286498-xarelto-lawsuit-claims-anticoagulant-caused-gastrointestinal-bleed/

Return to headline | Return to top
Ten People File Lawsuit Over Xarelto Bleeding Risks

Jan 14, 2016 | Righting Injustice

By Jennifer-Walker Journey

Ten individuals from various states have teamed up in a lawsuit against Bayer Healthcare and Johnson & Johnson subsidiary Janssen Pharmaceuticalsclaiming the drug companies oversold the effectiveness of their blood thinner Xarelto.
Xarelto was approved by the Food and Drug Administration (FDA) in 2011, the second in a new class of anticoagulants designed to go head-to-head with the long-used warfarin. The medication is approved to prevent blood clots in patients with atrial fibrillation, treat and prevent deep vein thrombosis and pulmonary embolism, and prevent blood clots in patients who have recently undergone hip or knee replacement surgery.
The lawsuit, filed in St. Clair Count Circuit Court in Illinois, claims Bayer and Janssen designed, researched, developed and distributed Xarelto as a safe and effective treatment. However, in the course of marketing the drug, the lawsuit alleges the defendants did not fully disclose the potential risks. Xarelto has been linked to serious bleeding events including gastrointestinal bleeds, brain bleeds and bleeding deaths.
The lawsuit claims that the drug companies received a letter from the FDA in June 2013, alleging their claims were misleading. Despite this warning, Bayer and Janssen continued to marketXarelto to doctors without warning of the risks. The suit charges the drug companies with strict product liability, intentional infliction of emotional distress, fraud, negligence, negligent misrepresentation, express and implied warranty, survival action, and wrongful death.
Plaintiffs include Robert Atkins, Charlene Bolen, individually and as special administrator for Barbara Bradley (deceased); Faye Bagley Cook, Sarah Lynn Croll, individually and as special administrator for Charloee Croll (deceased); Clifford Howard, Ronald Kendall, James Perkins, Teresa Pruitt, Mile Tuiolemotu, and Kathy Baker, individually and as special administrator for Martha Watson (deceased).
The lawsuit is one of hundreds waged against Bayer and Janssen over Xarelto bleeding risks.
http://www.rightinginjustice.com/news/2016/01/14/ten-people-file-lawsuit-over-xarelto-bleeding-risks/

Return to headline | Return to top
Xarelto Lawsuit BMJ Study Notes Potential Twofold Increased Risk Of GI Bleed

Jan 15, 2016 | Blood Thinner Help

By Joseph Osborne

BloodThinnerHelp.com reports on summer studies which link blood thinning drug Xarelto to dangerous bleeding events, such as spontaneous vitreous hemorrhages and gastroinstestinal bleeds. As Xarelto lawsuit numbers continue to grow, and focus turns to the current multidistrict litigation which has consolidated them, many are beginning to discuss the serious side effects which have become linked to the drug. Plaintiffs involved in the lawsuits point to studies from the summer of 2015 which highlight some concerning information.
A study published by JAMA Ophthalmology on June 25th of 2015 noted that researchers had found a connection between the use of rivaroxaban (the generic form of Xarelto) and an increased risk of spontaneous vitreous hemorrhage, which is bleeding of the eyes.
“The risk of hemorrhage may be particularly elevated during the transition period when patients are switched from baseline anticoagulant to rivaroxaban therapy and are taking both anticoagulants simultaneously,” the researchers involved noted.
This is a special warning which consumers should be made aware of, as many switch from traditional blood thinners to Xarelto on a regular basis. Plaintiffs state, however, that manufacturers of the drug, Bayer AG and Janssen Pharmaceuticals, have been negligent in properly releasing safety warning information to the public, a problem that plaintiffs believe has cost some their lives.
An additional study regarding the blood thinner was published in BMJ in April of 2015, and it pointed to the fact that patients who are treated with Xarelto (rivaroxaban) may be as much as doubling their risk of suffering from gastrointestinal bleeds as those who take warfarin (a traditional blood thinner). “...we cannot rule out...a more than twofold higher risk of bleeding with rivaroxaban compared with warfarin,” they stated.
Lawsuits surrounding these issues are currently awaiting trial. Nearly 3,000 cases have been filed across the U.S., and over 2,800 cases have been consolidated to form MDL no. 2592 by the JPML. These cases are being overseen by the Honorable Judge Eldon E. Fallon.
Attorney Joseph Osborne understands the devastating effects of uncontrollable bleeding episodes. He also believes that there is still time for other cases to join the ever-growing MDL. He is currently working to help those who have not yet filed, but who have suffered health issues that they connect to Xarelto to explore their legal rights. These individuals may be entitled to legal action and significant compensation. To help encourage them to pursue their deserved justice, Attorney Osborne is currently offering free consultations for those who qualify.
To request additional information or ask questions, please contact attorney Joseph Osborne by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2802770#ixzz3xKQcnjhI

Return to headline | Return to top

Full Text of Articles Below

Add recipients

Suggested